FEV1 increased in patients with aspirin-tolerant asthma while on standard asthma treatment but declined in patients with aspirin-exacerbated respiratory disease.
Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol provided greater increases in lung function compared to once-daily fluticasone furoate/vilanterol in patients with poorly controlled asthma.
Children with asthma and atopic dermatitis experience worse sleep and lung function outcomes compared with children with asthma alone.
In a real-world setting, biologic agents offered diverse clinical benefits in patients with asthma with and without chronic rhinosinusitis.
Epinephrine is more often prescribed for venom allergy and idiopathic anaphylaxis than for food allergy despite its potential as a life-saving drug for allergic reactions.
Researchers evaluated the efficacy of dupilumab for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
Treatment with 300 mg lanadelumab every 2 weeks significantly reduced monthly hereditary angioedema attack rates compared with the 3-month historic baseline.
GATA3 group 2 innate lymphoid cells may play a novel role in the pathogenesis of sputum eosinophilia in COPD.
Prenatal exposure to calcium carbonate antacids was associated with the development of food protein-induced allergic proctocolitis, a type of delayed inflammatory gut food allergy to protein, in offspring.
Although women are more likely than men to experience more severe asthma, they respond similarly to benralizumab therapy.